Literature DB >> 23882307

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome.

Sonal Choudhary1, Michael McLeod, Daniele Torchia, Paolo Romanelli.   

Abstract

Drug rash with eosinophilia and systemic symptoms syndrome is a severe idiosyncratic drug reaction with a long latency period. It has been described using many terms; however, drug rash with eosinophilia and systemic symptoms syndrome appears to be the most appropriate. This syndrome causes a diverse array of clinical symptoms, anywhere from 2 to 8 weeks after initiating the offending drug. Standardized criteria for the diagnosis have been developed; however, their utility remains to be validated. Unfortunately, the management of drug rash with eosinophilia and systemic symptoms syndrome is not well supported by strong evidence-based data.

Entities:  

Year:  2013        PMID: 23882307      PMCID: PMC3718748     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  36 in total

1.  Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions.

Authors:  B Rzany; O Correia; J P Kelly; L Naldi; A Auquier; R Stern
Journal:  Lancet       Date:  1999-06-26       Impact factor: 79.321

2.  HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia.

Authors:  J A Lieberman; J Yunis; E Egea; R T Canoso; J M Kane; E J Yunis
Journal:  Arch Gen Psychiatry       Date:  1990-10

3.  Clinical features of drug-induced hypersensitivity syndrome in 38 patients.

Authors:  S J Um; S K Lee; Y H Kim; K H Kim; C H Son; M S Roh; M K Lee
Journal:  J Investig Allergol Clin Immunol       Date:  2010       Impact factor: 4.333

4.  Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?

Authors:  I Garcia-Doval; L LeCleach; H Bocquet; X L Otero; J C Roujeau
Journal:  Arch Dermatol       Date:  2000-03

5.  Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases.

Authors:  Yi-Chun Chen; Hsien-Ching Chiu; Chia-Yu Chu
Journal:  Arch Dermatol       Date:  2010-08-16

6.  Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption.

Authors:  Y Kano; K Hirahara; Y Mitsuyama; R Takahashi; T Shiohara
Journal:  Allergy       Date:  2007-12       Impact factor: 13.146

7.  Genetic factors and risk of agranulocytosis from metamizol.

Authors:  V Vlahov; N Bacracheva; D Tontcheva; E Naumova; M Mavrudieva; P Ilieva; A Michailova
Journal:  Pharmacogenetics       Date:  1996-02

8.  Characterization of drug-specific T cells in lamotrigine hypersensitivity.

Authors:  Dean J Naisbitt; John Farrell; Gavin Wong; Jan P H Depta; Charlotte C Dodd; Josephine E Hopkins; Claire A Gibney; David W Chadwick; Werner J Pichler; Munir Pirmohamed; B Kevin Park
Journal:  J Allergy Clin Immunol       Date:  2003-06       Impact factor: 10.793

9.  Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan.

Authors:  C-C Chiou; L-C Yang; S-I Hung; Y-C Chang; T-T Kuo; H-C Ho; S Hu; H-S Hong; W-H Chung
Journal:  J Eur Acad Dermatol Venereol       Date:  2008-07-04       Impact factor: 6.166

10.  Association of HLA-DR5 with mucocutaneous lesions in patients with rheumatoid arthritis receiving gold sodium thiomalate.

Authors:  M Rodriguez-Pérez; J González-Dominguez; L Matarán; S Garcia-Pérez; D Salvatierra
Journal:  J Rheumatol       Date:  1994-01       Impact factor: 4.666

View more
  52 in total

1.  A Rare Case of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Glimepiride, the Unlikely Culprit.

Authors:  Nishanth Dev
Journal:  Maedica (Buchar)       Date:  2018-06

2.  Highly Probable Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome Associated With Lenalidomide.

Authors:  Anusha Shanbhag; E Ryan Pritchard; Kshitij Chatterjee; Drayton A Hammond
Journal:  Hosp Pharm       Date:  2017-07-18

3.  Lamotrigine-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).

Authors:  Karim Nathan; Abhishek Agarwal; Brian Gable; Miles McFarland
Journal:  BMJ Case Rep       Date:  2015-06-08

4.  Lamotrigine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) during primary Epstein-Barr virus (EBV) infection.

Authors:  Ibrahim Tawhari; Fawaz Tawhari; Mossab Aljuaid
Journal:  BMJ Case Rep       Date:  2018-01-23

5.  DRESS syndrome associated with influenza virus.

Authors:  Raghavendra L Girijala; Aishwarya Ramamurthi; David Wright; Young Kwak; Leonard H Goldberg
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-03-28

6.  Eosinophilic drug reactions detected by a prospective pharmacovigilance programme in a tertiary hospital.

Authors:  Elena Ramírez; Nicolás Medrano-Casique; Hoi Y Tong; Teresa Bellón; Rosario Cabañas; Ana Fiandor; Jessica González-Ramos; Pedro Herranz; Elena Trigo; Mario Muñoz; Alberto M Borobia; Antonio J Carcas; Jesús Frías
Journal:  Br J Clin Pharmacol       Date:  2016-10-12       Impact factor: 4.335

7.  A case of DRESS syndrome associated with carbamazepine treatment.

Authors:  Adem Dursun; Ayşe Kaçar Bayram; Nazan Ülgen Tekerek; Başak Nur Akyıldız; Hüseyin Per
Journal:  Turk Pediatri Ars       Date:  2018-03-01

8.  Vancomycin-associated drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: masquerading under the guise of sepsis.

Authors:  Luke Maxfield; Toni Schlick; Angela Macri; James Thatcher
Journal:  BMJ Case Rep       Date:  2017-10-19

9.  Drug reaction with eosinophilia and systemic symptoms in a child with N-methyl-d-aspartate receptor encephalitis.

Authors:  Kristen Taylor; Rajashree Srinivasan
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-08-30

10.  DRESS syndrome: an important differential for eosinophilia with systemic organ dysfunction.

Authors:  Whoasif Mukit; Richard Cooper; Harmesh Moudgil; Nawaid Ahmad
Journal:  BMJ Case Rep       Date:  2020-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.